A new tool to measure patient-reported outcomes (PROs) for laser-assisted in situ keratomileusis (LASIK) corrective eye surgery has been qualified by the US FDA’s Center for Devices and Radiological ...

Patient-reported outcome measures (PROMs) have become indispensable tools in the assessment and management of low back pain, providing direct insight into patients’ perceptions of pain intensity, ...

Patient-reported outcome measures (PROMs) have become integral to musculoskeletal rehabilitation, enabling clinicians to capture the patient’s perspective on pain, function and quality of life. Unlike ...

Access to patient-reported outcome (PRO) data significantly improved providers' consistency in assessing adverse events in patients with cancer, with the greatest improvements observed for ...

A large multinational clinical trial has found that giving healthcare providers access to European Organisation for Research and Treatment of Cancer (EORTC) patient-reported outcome (PRO) data ...

The pretreatment evaluation of patient-reported, health-related quality of life provides valuable prognostic information on ...

Researchers sought to determine the impact of an ePRO-based therapeutic monitoring system on hospitalizations, ED visits, and cost of care for patients with solid tumors.

Every day, across thousands of American hospitals, artificial intelligence quietly shapes decisions that determine patient ...

Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study This multicenter open-label RCT enrolled ...

Every year, hundreds of thousands of Americans undergo hip and knee replacement surgery. Surgeons can often predict how the operation itself will go. What surgeons have historically struggled to ...

An expert interview explores the scientific necessity of patient experience data in amyotrophic lateral sclerosis drug ...

Promising initial efficacy data with 60% volumetric response rate across doses and 29%* at the lowest tested dose of 100mg twice daily (BID) with ...